Fast track to drugability - through in-vitro biology
Attana Research Services are geared to quickly selected the right candidate molecules and targets. We provide you with biologically relevant information on crucial processes occur in the body. Attana is a Swedish company founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Attana develops and sells proprietary label free biosensors for biochemical, crude, sera and cell-based assays as well as contract research services. Attana’s products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences.
Humana Biosciences is a pre-clinical Contract Research Organization (CRO) with leading scientific capabilities in Respiratory, Gastro-Intestinal and Uro-Genital therapeutic areas. Every study they conduct is a custom designed study tailored specifically for the client. Their objective is to offer their customers the best predictive experimental models for chronic functional pathologies. Their ultimate ambition is to make pre-clinical drug development more predictive and faster. Their mission is to reduce the number of inefficacious candidates moving through to the later stages of clinical investigation by developing innovative experimental models (in vitro and in vivo). Partnering with Humana Biosciences also gives you on-demand access to ethically obtained human tissues.
e-Zyvec is a French Biotech Start-up founded in 2016 as a spin-off of the University of Lille 1. We are providing unique solutions in molecular biology to academical or industrial scientists working on research project with genetic engineering applications. Using our proprietary DNA assembly technology and our in-house developped web application, we can design and produce fully customized gene expression vectors, fitting exactly the requirements of your project. Getting vectors with e-zyvec is fast, accurate and unrestrictive.
Admescope is a contract research organisation (CRO) providing the pharmaceutical, biotechnology and veterinary industry with tailor made ADME-Tox services.
Our service offering covers research services for peptides, biologics and small molecules and is widely spread over the whole ADME-Tox area. The right assays are available, whether in the discovery or lead optimisation phase. The level of data interpretation can be customised according to customer preferences.
Currently Admescope serves customers in 28 countries on four continents.
AnalytiCon Discovery offers a complete Natural Product (NP) drug discovery solution, ranging from biomaterial acquisition, extraction, fermentation and screening to computational and medicinal chemistry, delivering NP-libraries with fully elucidated structures. AnalytiCon’s programs and collections of pure NPs (MEGAbolite) as well as of semisynthetic NP-analogues (NatDiverse) enable HT-screening of NPs.
evitria specializes in CHO-based transient expression of recombinant antibodies (including bispecific and fusion antibodies) for research purposes. evitria offers fast, cost-effective antibody expression with a flexible scale of production of purified antibody or supernatant according to client needs.
Headquartered in Zurich (Switzerland) and founded in 2010. evitria has since performed more than 55,000 transfections and produced more than 10,000 antibodies for its global customer base and excels with its benchmark-setting speed, reliability and quality.
In terms of antibody design evitria offers bispecific antibodies, fusion antibodies including Fc fusion proteins, antibody framework switching, Isotype switching, Glyco-engineering, ADCC modulation, chimerisation and humanization.
evitria has become one of the leading providers of custom-made recombinant antibodies and services for a broad range of clients from research institutions and start-ups to globally operating biotechnology and biopharmaceutical companies.
Ardigen is a Life Science computational partner in the era of Artificial Intelligence. We provide comprehensive services that leverage our domain knowledge and expertise in bioinformatics, machine learning and software engineering together with our proprietary technology. Ardigen platforms for neoepitope, biomarker, and microbiome research facilitate the improvement of the response rates in immuno-oncology.
Selvita is an integrated service provider aiming to deliver a set of comprehensive solutions supporting customers and projects within area of drug discovery, regulatory studies, as well as research and development.
ChemAxon is a leading cheminformatics company, with headquarters in Budapest, Hungary and offices in the US, they provide chemical software development platforms mostly for the biotechnology and pharmaceutical industries - but any chemist might find us useful.
Known for their rapid and high-quality technical support, they develop their tools together with their users (the reason we have good quality software); and because they support academic research and teaching like no one else in the industry!
Well, among many other things, you can draw & view chemical structures with Marvin Suite; manage and search your compounds with JChem tools; search your database in Excel or in their Instant JChem interface; perform a variety of calculations and predictions; cluster, screen, fragment or synthesize your compounds virtually and deal with Markush structures.
Sai Life Sciences is built on the bedrock of partnership. They work with innovator pharma and biotech companies to accelerate the discovery, development and manufacture of complex small molecules for a healthier tomorrow. Their Vision is to support global innovator partners bring 25 new medicines to life by 2025. And they are well on that journey.
Cellecta provides HT loss-of-function genetic screening services for the discovery and functional characterization of novel therapeutic targets. They offer pooled lentiviral shRNA and CRISPR libraries, pooled library screening and analysis by NGS, targeted RNA-Seq for biomarker discovery, lentiviral reagents, and stable cDNA, shRNA, and CRISPR constructs and isogenic cell lines.
MaxWell Biosystems AG provides solutions to advance basic neuroscience research and accelerate preclinical drug discovery. They have built MaxOne, the most powerful electrophysiology platform for recording and stimulating electrogenic cells (brain, retina, and heart cells) in vitro. MaxOne is a CMOS-based high-density microelectrode array with 26,400 electrodes, 1024 low-noise readout channels, and 32 stimulation channels. MaxOne allows extracting single cell and network parameters that facilitate phenotypic screening and drug toxicity/efficacy testing.
Sino Biological is an international reagent supplier and service provider.The company specializes in recombinant antigen production and antibody development.The company’s ever-growing portfolio of products includes recombinant proteins, monoclonal antibodies,ELISA assay kits,expression clones,cell culture media,and other molecular biology tools.The company also offers a variety of customized services,mainly focusing on recombinant production of antigens and antibodies.Sino Biological is dedicated to virology and infectious disease research.Its newly launched ProVirTM collection is the world’s largest viral antigen bank,carrying over 800 products from 350 strains of viruses.
I am Senior Director Sales & Marketing for WuXi LabNetwork, WuXi’s online marketplace for research products. My goal is to support the WuXi AppTec vision that every drug can be made and every disease can be treated through building the open-access platform with the most comprehensive capabilities and technologies in the global healthcare industry.
From small molecule R&D and manufacturing, cell and gene therapy to drug R&D and medical device testing and clinical services, WuXi offers a platform of services and technologies in breadth and depth exceeding that of competitors. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D.
Demand for new and more affordable therapies has never been greater. Better therapies require open-access approaches to lower the entry barrier for innovation, and to harness collective capabilities and experience to improve the chance of success. At WuXi, our commitment is to make the most meaningful difference to patients and society by enabling anyone and any company with great minds to discover and develop new medicines and products more efficiently and cost effectively to benefit patients.
It is difficult to pinpoint which is the biggest, but given the direction of the industry as a whole, our goal of reaching out to and getting integrated with smaller companies and start-ups is a key challenge. The landscape is changing and small companies are coming about at a rapid pace and in a variety of new technologies and geographies.
Even with the increase in knowledge and technology, barriers to entry are still substantial. There are still many resources involved in starting a venture and new companies with limited capabilities need to seek assistance in advancing their technology to effective therapeutic practice.
One challenge is speeding up timelines. A platform company like WuXi, with a full suite of services and capabilities, can help clients cut timelines by years by removing the handoff costs associated with dealing with multiple vendors.
Sharing of information is another one. There is no doubt that information gained by organizations is often held in confidence so that the broader intellectual community cannot act on it for the benefit of scientific advancement. We support independent organizations, such as the Pistoia Alliance, that work with industry to create and promote sharing platforms.
We continue to seek new relationships and we expect the DDIP to help with that. We expect to learn of new approaches and new technologies while making meaningful new connections with potential partners.
I came to Sai Life Sciences from global telecom firm with a finance background to help with business development. It has been a remarkable experience working with all our great partners and being a small part of their success stories. In the 14 years I have been with Sai, it has been great to witness our transformation from a 30 member chemistry services provider to an integrated discovery, development and commercial service provider with over 2,000 employees.
At Sai, we truly focus on our partner’s success. Our fundamental belief is that we can add true investor value by building long terms customer relationships, as opposed looking at profitability at a transactional level. This ensures that we take a long term view of the business over a 10 year horizon, enabling us to make larger investments in the business and offering customers the framework to have a truly collaborative relationship. We are committed to our motto of “Making things better together”.
Discovery Technologies: Placing the right bets on what technologies you want to adopt. Every move involves substantial investment and takes times to implement. This really presents some high risk reward choices companies will have to make.Information Technology: We are in a major transition phase where IT technology will be integral part of how we innovate and how we analyze data. Every company needs to develop the core IT architecture in their organizations now, if they want to stay relevant. Regulatory framework: The regulations are getting much more stringent. How do you stay fast and still ensure minimum regulatory risk.